How Digestive Enzymes Work and When to Supplement

Evidence Review

Exocrine Pancreatic Insufficiency: The Best-Established Use

De la Iglesia-García et al. (PMID 27941156), published in Gut (2017), conducted a systematic review and meta-analysis of pancreatic enzyme replacement therapy in chronic pancreatitis. The review analyzed 8 randomized controlled trials involving 278 patients. PERT significantly improved the coefficient of fat absorption (CFA) compared to placebo, with a weighted mean difference of +13% (95% CI: 7–19%, p < 0.001). Quality of life measures also improved. Importantly, even with adequate PERT, fat absorption rarely normalized completely, reflecting the severity of pancreatic damage in chronic pancreatitis. The review found acceptable safety profiles across all included studies, with no serious adverse events attributable to enzyme therapy. This is among the highest-quality evidence in the digestive enzyme literature — multiple RCTs with objective malabsorption outcomes.

Rational Use in Clinical Practice

Ketwaroo and Graham (PMID 31482505), in a 2019 review published in Advances in Experimental Medicine and Biology, outlined the clinical rationale for enzyme therapy across the spectrum of pancreatic insufficiency. The authors emphasize that EPI is underdiagnosed and that a therapeutic trial of PERT is often warranted even when fecal elastase testing is borderline (100–200 mcg/g). They review evidence showing that PERT reduces post-prandial pain in chronic pancreatitis independently of its effects on malabsorption — an important finding suggesting enzymes may reduce pancreatic stimulation and stretch-mediated pain. The paper provides practical dosing guidance and notes that inadequate dosing (particularly underdosing of lipase) is the most common reason for treatment failure in clinical practice.

Functional Digestive Complaints: Promising but Limited Evidence

Graham et al. (PMID 30101562), published in the Journal of Digestive Diseases (2018), evaluated enzyme therapy for "functional bowel disease-like post-prandial distress" — symptoms like bloating, fullness, discomfort, and loose stools that occur after eating in people without identifiable pathology. The paper reviews data from multiple small trials and case series. A single-center study within the review found that multi-enzyme supplementation (containing lipase, protease, and amylase) significantly reduced post-meal symptoms scores compared to placebo in patients with functional dyspepsia-like symptoms, though sample sizes were small (n = 28–45). The authors conclude that a subset of patients labeled with functional bowel disease may actually have mild enzyme insufficiency as the proximate cause — and that a therapeutic trial of broad-spectrum enzymes is low-risk and clinically reasonable. This is an important conceptual contribution even if the individual trials are underpowered.

IBS and Inflammatory Bowel Disease

Spagnuolo et al. (PMID 28724171), published in the European Review for Medical and Pharmacological Sciences (2017), randomized 43 patients with IBD or IBS to receive either conventional therapy alone or conventional therapy plus a combination of beta-glucan, inositol, and digestive enzymes for four weeks. The supplemented group showed statistically significant reductions in abdominal pain scores, bloating, and flatulence (p < 0.05 for each). While the study design makes it impossible to isolate the contribution of the enzyme component specifically — since beta-glucan and inositol also have independently documented effects — this represents direct clinical evidence that enzyme-containing formulations improve quality of life in these populations. The sample size (23 vs. 20 patients) limits generalizability, but the findings align with mechanistic expectations.

Lactase: Strongest OTC Evidence

Baijal and Tandon (PMID 33490624), published in JGH Open (2020), conducted a randomized double-blind crossover trial in 47 adults with confirmed lactose intolerance. Participants received either lactase tablets or placebo before consuming a standardized lactose challenge (50g lactose). Lactase significantly reduced cumulative hydrogen breath excretion by 55% over 180 minutes (p < 0.05) compared to placebo, indicating substantially better lactose digestion. Clinical symptom scores — measuring bloating, cramping, diarrhea, and flatus — were also significantly improved (p < 0.05). This is the most methodologically clean trial of a specific digestive enzyme in OTC use: double-blind, crossover design, objective biomarker (breath hydrogen), and patient-reported outcomes. It provides strong, actionable evidence that lactase tablets reliably reduce symptoms and improve digestion of lactose-containing foods.

Comprehensive Review of Enzyme Supplementation

Roxas (PMID 19152478), published in Alternative Medicine Review (2008), provides a broad narrative review of enzyme supplementation across multiple digestive conditions — malabsorption syndromes, IBS, IBD, and food intolerances. The review identifies the foundational principle: whenever digestion is incomplete, undigested substrates become substrates for colonic bacterial fermentation, generating gas and inflammatory byproducts. This unified mechanism explains why broad-spectrum enzyme blends may help across seemingly disparate digestive complaints. The review also covers plant-derived enzymes — bromelain, papain, and papaya enzymes — noting their broader pH activity range compared to animal-derived sources and their established use in reducing post-meal discomfort in healthy volunteers. While some of the cited studies are older and methodologically limited, the mechanistic framework remains valid and is supported by more recent work.

Overall Evidence Assessment

The evidence for digestive enzyme supplementation exists on a spectrum. For exocrine pancreatic insufficiency, the evidence is strong — multiple RCTs show objective improvements in fat absorption, and PERT is standard of care. For lactose intolerance and lactase supplementation, evidence from controlled trials is solid and the effect is reliable. For functional complaints like bloating, IBS-like symptoms, and general post-meal discomfort, the evidence is growing but still limited by small sample sizes and multi-ingredient study designs. There are no significant safety concerns at standard doses, making a therapeutic trial low-risk. The field would benefit from larger, well-designed RCTs specifically targeting functional enzyme insufficiency as a treatable cause of common digestive symptoms.